

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway,
Goregaon (East), Mumbai – 400063 India
Tel. : (91-22) 43244324 / 1234
Fax.: (91-22) 43244343
CIN: L24230GJ1993PLC019050, www.sunpharma.com



February 19, 2018

National Stock Exchange of India Ltd,

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

NSE Code – SUNPHARMA

BSE Ltd,

Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

BSE Code – 524715

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

This is to inform you that one of the wholly owned subsidiaries of the Company has increased its shareholding in Ranbaxy Malaysia Sdn Bhd, Malaysia, by way of further purchase of 386,865 shares of face value of MYR 1.00 each (equivalent to 4.84%) of Ranbaxy Malaysia Sdn Bhd.

Ranbaxy Malaysia Sdn Bhd., is a subsidiary of the Company, and the total shareholding of Sun Pharmaceutical Industries Ltd., alongwith its wholly owned subsidiary is 85.90%, prior to this purchase of shares.

Post completion of this purchase of shares, the total holding of the Company alongwith its wholly owned subsidiary will increase from 85.90% to 90.74% in Ranbaxy Malaysia Sdn Bhd.

The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as per 'Annexure A'.

This is for your information and record.

Yours faithfully,

For Sun Pharmaceutical Industries Limited,

Ashok I Bhuta
Compliance Officer

Enclosures:

1. Annexure A

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway,
Goregaon (East), Mumbai – 400063 India
Tel. : (91-22) 43244324 / 1234
Fax.: (91-22) 43244343
CIN: L24230GJ1993PLC019050, www.sunpharma.com

**Annexure A**

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	i) Name of the Target Entity : “Ranbaxy Malaysia Sdn Bhd.” (“Target Entity”) ii) Details of the Target Entity: 2017 Sales: MYR 95.32mn MYR = Malaysian Ringgit
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”;	The acquisition of shares would not fall within related party transaction(s), as the shares are being acquired by Sun Pharma (Netherlands) BV from Eleven Local (Malaysian) shareholders Group companies have an interest in the entity being acquired as Sun Pharmaceutical Industries Ltd. and Sun Pharma (Netherlands) BV are already the existing shareholders of the Target Entity among other shareholders in the Target Entity. The promoter/ promoter group/ group companies of Sun Pharmaceutical Industries Limited have no interest in the Target Entity. The shareholding of Sun Pharmaceutical Industries Ltd., alongwith its wholly owned subsidiary, in the Target Entity is 85.90%, prior to this purchase of shares and hence the Target Entity is already a subsidiary of the Company.
c) Industry to which the entity being acquired belongs;	Pharmaceuticals

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway,
Goregaon (East), Mumbai – 400063 India
Tel. : (91-22) 43244324 / 1234
Fax.: (91-22) 43244343
CIN: L24230GJ1993PLC019050, www.sunpharma.com



d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Increase the current shareholding of the Target Entity from 85.90% to 90.74%
e) Brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable.
f) Indicative time period for completion of the acquisition;	28 th February, 2018
g) Nature of consideration - whether cash consideration or share swap and details of the same;	Cash
h) Cost of acquisition or the price at which the shares are acquired;	MYR 4.29 per share of face value MYR 1.00 each. Total consideration is MYR 1,659,650.85 for 386,865 shares
i) Percentage of shareholding / control acquired and / or number of shares acquired;	Sun Pharma (Netherlands) BV, a wholly owned subsidiary of the Company has concluded a transaction for purchasing 386,865 shares of face value MYR 1.00 each of the Target Entity. With this acquisition the total shareholding of Sun Pharma (Netherlands) BV in the Target Entity would increase from 3,682,915 (46.03%) shares to 4,069,780 shares (50.87%). Current shareholding of Sun Pharmaceutical Industries Ltd in the Target Entity is 3,189,248 shares (39.87%) which shall remain the same. The total shareholding of Sun Pharmaceutical Industries Ltd., alongwith its wholly owned subsidiary in the Target Entity will increase from 85.90% to 90.74% post this purchase of shares.

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway,
Goregaon (East), Mumbai – 400063 India
Tel. : (91-22) 43244324 / 1234
Fax.: (91-22) 43244343
CIN: L24230GJ1993PLC019050, www.sunpharma.com



j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Brief background: The Target Entity is engaged, <i>inter alia</i>, in manufacturing and selling of pharmaceutical products in Malaysia and the Republic of Singapore. Date of incorporation: 26-08-1982 Turnover of last 3 years: 1. Year Apr 2014-March 2015 –MYR 67.86mn 2. Year Apr 2015-March 2016 – MYR 77.82mn 3. Year Apr 2016-March 2017 –MYR 95.32mn Line of business: Pharmaceuticals Country in which the acquired entity has presence: Malaysia and Singapore
---	---

Date : February 19, 2018